Wednesday, July 8, 2026

Patent intelligence · US

US 12173307

Methods for the purification of viral vectors

granted A61KA61K48/0091
Status granted
Linked drugs 2
Pipeline programs 6
Years to expiry 18
Applicant portfolio 140
Patent details — US 12173307

Quick answer

US 12173307 (Methods for the purification of viral vectors) is held by BIOVERATIV THERAPEUTICS INC.. Status: granted. Granted Dec 24, 2024. Expires Dec 19, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
14
CPC classes
A61K, A61K48/0091

More from BIOVERATIV THERAPEUTICS INC.

Related pharmaceutical patents in our USPTO index.

  1. US 12403164

    Lentiviral vector formulations

    BIOVERATIV THERAPEUTICS INC. · Expires Aug 28, 2045

    granted
  2. US 12403183

    Factor VIII polypeptide formulations

    BIOVERATIV THERAPEUTICS INC. · Expires Aug 28, 2045

    granted
  3. US 12391750

    Anti-C1S antibodies and methods of use thereof

    Bioverativ USA Inc. · Expires Aug 14, 2045

    granted
  4. US 12371747

    Methods of reducing immunogenicity against factor VIII in individuals undergoing factor VIII therapy

    BIOVERATIV THERAPEUTICS INC. · Expires Jul 24, 2045

    granted
  5. US 12364774

    Nucleic acid molecules and uses thereof for non-viral gene therapy

    BIOVERATIV THERAPEUTICS INC. · Expires Jul 17, 2045

    granted
  6. US 12268688

    Compositions and methods of use for modified release minoxidil

    Veradermics Incorporated · Expires Apr 3, 2045

    granted
  7. US 12257288

    Methods of inducing immune tolerance to clotting factors

    BIOVERATIV THERAPEUTICS INC. · Expires Mar 20, 2045

    granted
  8. US 12240917

    Anti-complement C1s antibodies and uses thereof

    Bioverativ USA Inc. · Expires Feb 27, 2045

    granted

Frequently asked questions

What is US patent 12173307?

US 12173307 (Methods for the purification of viral vectors) is held by BIOVERATIV THERAPEUTICS INC.. Status: granted. Granted Dec 24, 2024. Expires Dec 19, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 12173307?

BIOVERATIV THERAPEUTICS INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 140 pharmaceutical patents for this assignee.

When does US 12173307 expire?

Our index shows an expiration date of Dec 19, 2044 (18 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.